Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN( Alzheimer's Patent Application

Intellect application supported by written declaration from independent, world renowned academic expert in therapeutic antibodies NEW YORK, Nov. 3, 2011 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it has filed a response and request for continued examination (RCE) in its antibody methods appli...continued ILNS  memory intellect Healthcare

URL: http://www.investorpoint.com/news/INTHPINK/45816515/